Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
XGEVA (denosumab) - Important Safety Information from Amgen as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
04/09/2012
Problem Or Issue:
Important Safety Information communication from Amgen on the risk of severe symptomatic hypocalcaemia associated with the use of denosumab and the risk of late onset of hypocalcaemia.
Important Safety Information - XGEVA (denosumab)
« Back
Date Printed: 15/05/2024